Protocol: CDISCPILOT01                                                                  Page  1 of 1 
Population: Intent-to-Treat 
Table 14-1.02 
Summary of End of Study Data 
 
 
[1] Fisher's exact test. 
[2] Based on either patient/caregiver perception or physician perception. 
Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\adsl2.sas                     21:02 Monday, June 26, 2006 
 
Placebo 
(N=86) 
Xanomeline 
Low Dose 
(N=84) 
Xanomeline
High Dose
(N=84) 
Total 
(N=254) p-value[1]
 
Completion Status: 
  Completed Week 24 
  60 ( 70%)   28 ( 33%)   30 ( 36%)  118 ( 46%) <.0001 
  Early Termination (prior to Week 24)   26 ( 30%)   56 ( 67%)   54 ( 64%)  136 ( 54%)
 
  Missing 
   0 (  0%)    0 (  0%)    0 (  0%)    0 (  0%)
 
 
Reason for Early Termination (prior to Week 24): 
  Adverse Event 
   8 (  9%)   44 ( 52%)   39 ( 46%)   91 ( 36%) <.0001 
  Death 
   1 (  1%)    1 (  1%)    0 (  0%)    2 (  1%)
 
  Lack of Efficacy[2] 
   3 (  3%)    0 (  0%)    1 (  1%)    4 (  2%) 0.3281 
  Lost to Follow-up 
   1 (  1%)    0 (  0%)    0 (  0%)    1 (  0%)
 
  Subject decided to withdraw 
   9 ( 10%)    8 ( 10%)    8 ( 10%)   25 ( 10%)
 
  Physician decided to withdraw subject    1 (  1%)    0 (  0%)    2 (  2%)    3 (  1%)
 
  Protocol criteria not met 
   1 (  1%)    0 (  0%)    2 (  2%)    3 (  1%)
 
  Protocol violation 
   1 (  1%)    1 (  1%)    1 (  1%)    3 (  1%)
 
  Sponsor decision 
   1 (  1%)    2 (  2%)    1 (  1%)    4 (  2%)
 
  Missing 
   0 (  0%)    0 (  0%)    0 (  0%)    0 (  0%)
 
 
